MolecularMD Announces Issuance of Patent Covering Methods for Therapeutic Resistance Monitoring in Lung Cancer Patients
Portland, OR, December 9, 2011 — MolecularMD Corp. today announces the issuance of a patent entitled “Methods and Compositions for Detecting a Drug Resistant EGFR Mutant.” The newly issued U.S. Patent is based on the pioneering work of researchers at Memorial Sloan-Kettering Cancer Center to identify causes of resistance in patients treated with epidermal growth factor receptor (EGFR) targeted therapies erlotinib (Tarceva™) or gefitinib (Iressa™)1. MolecularMD has exclusively licensed the commercial rights to this intellectual property which covers methods for detecting the EGFR T790M mutation.
Medco Partners with MolecularMD on Personalized Medicine Program for Chronic Myeloid Leukemia
FRANKLIN LAKES, NJ and PORTLAND, OR, June 2, 2011 — Medco Health Solutions, Inc. (NYSE: MHS) and MolecularMD Corp. today announce the launch of a personalized medicine program for chronic myeloid leukemia (CML) patients. Through this program, Medco will offer patients diagnosed with CML a molecular test known as qRT-PCR (quantitative real-time polymerase chain reaction) BCR-ABL to monitor the disease.
ARIAD AND MOLECULARMD ANNOUNCE COLLABORATION FOR A COMPANION DIAGNOSTIC TEST FOR THE T315I BCR-ABL MUTATION IN PATIENTS WITH CML
Cambridge, MA, and Portland, OR, March 28, 2011 — ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and MolecularMD Corporation today announced an exclusive collaboration agreement in which MolecularMD will develop and commercialize a companion diagnostic test to identify the T315I mutation of the BCR-ABL gene in patients with chronic myeloid leukemia (CML) and Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL).
MolecularMD Corp. Obtains Exclusive License from NYU and MSKCC for BRAF Melanoma Assay
Portland, OR, October 17, 2010 — MolecularMD Corp. announced today that it has entered into a licensing agreement with New York University (NYU) and Memorial Sloan-Kettering Cancer Center (MSKCC). The agreement grants MolecularMD exclusive US commercial rights to patented intellectual property pertaining to the detection of the BRAF V600E mutation (US patent No. 7,442,507 B2).
MolecularMD Establishes New Operations Facility to Support Growth in Personalized Cancer Medicine Business
Portland, OR, October 28, 2009—MolecularMD Corp announced today that it has moved their core operations to a expanded dedicated facility with capacity and functionality to support the expansion of its cancer molecular diagnostics business...
MolecularMD Establishes New Operations Facility to Support Growth in Personalized Cancer Medicine Business
Portland, OR, October 28, 2009—MolecularMD Corp announced today that it has moved their core operations to a expanded dedicated facility with capacity and functionality to support the expansion of its cancer molecular diagnostics business...
MolecularMD and Mayo Clinic Enter into Sub-License Agreement for the Detection of Drug Resistant Mutations in Leukemia Patients.
Portland, OR, April 15, 2009—MolecularMD Corp, a developer and provider of cancer-based pharmacogenomic diagnostic tests, announced today that it has granted a sub-license agreement for the detection of ABL kinase mutations in Chronic Myelogenous Leukemia (CML) patients...
Ballast Point Ventures Invests In MolecularMD Corporation
St. Petersburg, Fla, January 15, 2009—Ballast Point Ventures (BPV), a venture capital firm affiliated with Raymond James Financial, Inc. (NYSE-RJF) today announced it has closed a growth equity investment in MolecularMD Corporation....
Exclusive Rights to Patented IP Related to Detection of Resistant BCR-ABL Mutations
PORTLAND, Ore., May 27, 2008—MolecularMD Corp, a developer and provider of cancer-based molecular diagnostics, announced today that it has entered into a license agreement with the Oregon Health & Science University to obtain exclusive commercial...
MolecularMD Joins CML Alliance to Provide Standardized RT-PCR BCR-ABL Patient Monitoring Diagnostics
PORTLAND, Ore., August 6, 2007—MolecularMD, a developer and provider of cancer-based molecular diagnostics, today announced its participation as a preferred provider of Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) patient...
OHSU To Offer Personalized Cancer Diagnostics In New Biotechnology Company
PORTLAND, Ore., May 16, 2007—Oregon Health & Science University has signed an agreement with MolecularMD, a private, molecular diagnostics company founded by scientific investigators including Brian Druker, M.D. The agreement gives OHSU an ownership...
MolecularMD Enters into Agreement with Breakthrough Therapeutics to Support Phase II Clinical Trial
PORTLAND, Ore., August 15, 2006—MolecularMD, a molecular oncodiagnostics company, has recently entered into an agreement with Breakthrough Therapeutics, a private oncology company based in Greenwich, CT, to monitor residual disease levels in patients...
ChemGenex Teams with MolecularMD
MELBOURNE, Australia, and MENLO PARK, California U.S.A., June 26, 2006—ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) today announced an alliance with MolecularMD, Inc., a leading provider of molecular diagnostic services, including drug...
Upcoming Events
No events posted at this time